Work

Response to the letter Re: Comparative overall survival of CDK4/6 inhibitors plus an aromatase inhibitor in HR+/HER2− metastatic breast cancer in the US real-world setting

Year: 2025

Type: article

Abstract: Camoz et al. provided comments on our recently published article ‘Comparative overall survival of CDK4/6 inhibitors plus an aromatase inhibitor in HR+/HER2− metastatic breast cancer in the US real-world setting’.1 We appreciate their feedback and have responded to their comments in detail below.

Source: ESMO Open

DOI: 10.1016/j.esmoop.2025.105297

Authors: H.S. Rugo, R.M. Layman, F. Lynce, X. Liu, B. Li, L. McRoy, A.B. Cohen, M. Estevez, G. Curigliano, A. Brufsky

Institutions: City Of Hope National Medical Center, City of Hope, The University of Texas MD Anderson Cancer Center, Dana-Farber Cancer Institute, Pfizer (United States), NYU Langone Health, Flatiron Health (United States), New York University, University of Milan, European Institute of Oncology, UPMC Hillman Cancer Center, University of Pittsburgh Medical Center

Language: English

Topic: Advanced Breast Cancer Therapies

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,910

Funders: Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, AstraZeneca, Roche, Sanofi, Gilead Sciences, F. Hoffmann-La Roche, Novartis Pharmaceuticals Corporation, Veracyte, Seagen, Daiichi-Sankyo, Genentech, Samsung, Foundation Medicine, Arena Pharmaceuticals

OpenAlex ID: W4411371091

FWCI:

Cites: 5

Cited by:

Related to: 10